Evidence map›Paper›PMID 41049944›Full record

ArticleCureus2025

Innovation in Onychomycosis Treatment Through Creative Compounding.

Kristine Hoffman, Matthew Gorski, Christian P Frey

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kristine HoffmanOrthopedics, Denver Health and Hospital Authority, Denver, USA.
Matthew GorskiOrthopedics, Denver Health and Hospital Authority, Denver, USA.
Christian P FreyPodiatry, Denver Health and Hospital Authority, Denver, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Onychomycosis is a common fungal nail infection, often presenting with nail discoloration, thickening, and brittleness. Despite the availability of oral and topical antifungal agents, recurrence rates remain high, and systemic therapies can pose risks such as hepatotoxicity and drug interactions. This case report describes an innovative treatment approach using a compounded topical preparation made by combining a crushed 250 mg oral terbinafine tablet with an over-the-counter 1% tolnaftate nail lacquer. A healthy 28-year-old female presented with diffuse toenail onychomycosis affecting all digits. After declining oral therapy, she initiated daily application of the compounded lacquer for 10 months. Weekly complete removal and reapplication were performed, and the vial was shaken before each use to maintain a homogenous mixture. The patient documented progress photographically and reported high satisfaction with a significant improvement in nail appearance. No adverse effects were noted. This topical use of pulverized terbinafine takes advantage of the drug's favorable molecular profile for nail penetration, offering targeted treatment with minimal systemic absorption. The estimated daily delivery of terbinafine per nail was approximately 0.4 mg, a potentially therapeutic dose when applied consistently over time. This case supports the potential of creative compounding in expanding safe and patient-friendly treatment options for onychomycosis, especially for individuals who are unable or unwilling to take oral antifungals. Further studies are needed to evaluate the efficacy, pharmacokinetics, and broader applicability of this approach.

Indexed as

compounded medicationnail lacqueronychomycosisterbinafinetopical antifungal therapy

Identifiers

PMID41049944
PMCPMC12491616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.